Drug Search Results
More Filters [+]

Clofarabine

Alternative Names: clofarabine, clolar
Latest Update: 2024-08-21
Latest Update Note: Clinical Trial Update

Product Description

Clofarabine is used to treat acute lymphoblastic leukemia (ALL; a type of cancer of the white blood cells) in children and young adults 1 to 21 years old who have already received at least two other treatments. Clofarabine is in a class of medications called purine nucleoside antimetabolites. It works by killing existing cancer cells and limiting the development of new cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a607012.html)

Mechanisms of Action: Apoptosis Stimulant

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Japan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Clofarabine

Countries in Clinic: Australia, China, United States, Unknown Location

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma

Phase 2: B-Cell Leukemia|Lymphoma, B-Cell|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TOT17

P3

Active, not recruiting

Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma

2026-09-30

ALLR18

P2

Completed

Acute Lymphoid Leukemia|Lymphoma, B-Cell|Precursor Cell Lymphoblastic Leukemia-Lymphoma|B-Cell Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

2021-07-24

CTR20132344

P3

Recruiting

Unknown

None

CTR20171404

P2

Active, not recruiting

Acute Lymphoid Leukemia

None

Recent News Events